Drugs / Peg-IFNα2a
Peg-IFNα2a
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04980482 | Oct 2021 → Mar 2025 | chronic hepatitis B virus infection | Arbutus Biopharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00537407 | Sep 2007 → Apr 2010 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01906580 | Jul 2011 → Jul 2016 | chronic hepatitis B virus infection | Beijing 302 Hospital | Unknown | No outcome recorded |
| Comparator or background therapy8 trials | ||||||
| Phase 2 | NCT05107778 Background | Jan 2022 → Nov 2023 | chronic hepatitis B virus infection | Ascletis Pharmaceuticals Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01335711 Background | Apr 2011 → Jun 2012 | chronic hepatitis C virus infection | ChronTech Pharma AB | Unknown | No outcome recorded |
| Phase 2 | NCT00996476 Background | Jul 2009 → Jan 2011 | chronic hepatitis C virus infection | Janssen Pharmaceutical K.K. | Completed | Mixed |
| Phase 2 | NCT00882908 Background | Jun 2009 → Apr 2010 | chronic hepatitis C virus infection | Tibotec Pharmaceuticals, Ireland | Completed | No outcome recorded |
| Phase 2 | NCT00395421 Background | Oct 2006 → Jun 2008 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT01226771 Background | Sep 2010 → Sep 2014 | chronic hepatitis C virus infection | Göteborg University | Completed | No outcome recorded |
| — | NCT01970904 Background | Oct 2013 → Mar 2015 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
| — | NCT00854802 Background | Jan 2009 → Sep 2010 | chronic hepatitis C virus infection | Debiopharm International SA | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFNα 2a | “SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)” NCT01335711 ↗11“PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.” NCT00882908 ↗ “PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day)” NCT01226771 ↗ |
| Known as | PegIFNa-2a | “PegIFNa-2a and ribavirin (PR)” NCT00996476 ↗ |
| Known as | peginterferon alfa-2a | “peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV)” NCT00882908 ↗ |
| Known as | Pegylated Interferon α-2a | “ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus” NCT05107778 ↗ |
| Modality | Protein / enzyme biologic | “pegylated interferon α-2a” NCT05107778 ↗ |
| Route | Subcutaneous | “180 μg subcutaneously (sc) once weekly” NCT00537407 ↗ |